ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP lowered its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 43.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 87,391 shares of the biotechnology company’s stock after selling 66,160 shares during the period. Advantage Alpha Capital Partners LP’s holdings in ADMA Biologics were worth $1,747,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Quest Partners LLC purchased a new position in ADMA Biologics during the 2nd quarter valued at about $29,000. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics in the third quarter valued at approximately $30,000. EntryPoint Capital LLC purchased a new position in shares of ADMA Biologics during the 1st quarter worth approximately $31,000. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $31,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics in the 3rd quarter valued at approximately $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Price Performance

ADMA stock opened at $21.47 on Tuesday. The stock has a market capitalization of $5.08 billion, a price-to-earnings ratio of 76.68 and a beta of 0.64. The stock’s fifty day simple moving average is $18.92 and its 200-day simple moving average is $15.05. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the company earned $0.01 EPS. Equities research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The trade was a 5.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is owned by company insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.